These findings bolster the case for tulisokibart as a targeted therapy against immuno-fibrosis, a biological mechanism known to accelerate disease progression in inflammatory bowel conditions. By addressing this underlying driver, Merck aims to differentiate the candidate from existing treatments in a crowded therapeutic landscape.

Following these results, the company is accelerating its broader research program for the drug. Tulisokibart is currently undergoing evaluation across seven distinct disease indications, reflecting Merck’s strategy to leverage the compound’s mechanism of action beyond bowel inflammation.